Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.40p -0.21% 1,646.40p 1,643.40p 1,644.00p 1,662.40p 1,639.00p 1,654.00p 7,731,290 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 22.3 81,735

Glaxosmithkline Share Discussion Threads

Showing 19526 to 19549 of 19875 messages
Chat Pages: Latest  783  782  781  780  779  778  777  776  775  774  773  772  Older
DateSubjectAuthorDiscuss
05/4/2019
16:11
My point is although nothing is guaranteed a share like GSK generally plods on for years and pays a steady dividend every few months.With smaller cap shares you are often buying something with far greater volatility and potential for loss and gain and sdi went for years doing nothing and not paying a dividend.Much is down to your appetite for risk and investment objectives.
tim 3
05/4/2019
14:28
One is much more likely to pick a real dud in the small cap market (eg Patisserie Valerie which ticked all the right boxes right up to the end) than in larger caps. As Tim3 implies, it's easy to prove how wise you are if you select statistics and time frames to suit your own thesis. A mix of high dividend yield large caps with small caps which pay more modest dividends works out even better over the long term. Twenty years of serious investing has taught me that - even with the occasional dramatic mistake in both small and large caps. Provided I hit around 7 out of 10 shares right, I am happy.... and reasonably successful in terms of dividends and growth.
grahamburn
05/4/2019
10:08
In that time frame yes but look at a longer timeframe say 2010 to 2017 and sdi basically went nowhere where as although gsk only went up a little you had a decent dividend each year which if reinvested would have given a much better performance.
tim 3
05/4/2019
10:06
Buywell - if you must ramp be honest and use the data from 2007 when SDI was £17 as opposed to 50p today.
toffeeman
05/4/2019
09:42
You guys probably think you are doing very well invested in GSK Well ... don't you ? .... come on admit it you do. Remember Ashley James ? He was my mentor ... crossed swords on another website before advfn was born when I was just a big-headed young upstart. I learnt a lot from Ashley and though we argued a lot ... I liked and respected his views ... even when he was wrong , hahaha Ash. Unfortunately he is no longer with us so today I have tried to help those less savvy investors on some other threads ... like Ash helped me ... by asking them to open their minds to looking at quality UK Small Cap Stocks , well managed , and with the right growth strategy in place. ''Dividends are NOT the be all and end all'', I have argued. ''Using company cash to buy more profit making company's is a better way'', I have said. I used a 3 year comparison chart of SDI V their company Barclays Bank, Lloyds Bank, Aviva, BP , and Glaxo Smith Kline were my choices All FTSE 100 stocks ... all paying dividends ... and in a mix of sectors seen as safe ... by some ... not me I would add. It was a NO CONTEST ... and SDI was a winner by knockout in each and every case Here it is in one picture GSK are in there at the bottom
buywell2
04/4/2019
13:06
Yesterday was a buying day.
abdullla
04/4/2019
12:15
Did you sell yesterday?
tradermichael
04/4/2019
10:11
Sold out at just over 16, phew, will watch them do the usual and slide back to the low 15's. Totally range bound. People bang on about the divi which is ok but there are income funds that pay more without the stock specific risk, if you want capital growth buy astra on weakness, amazing pipeline which Glaxo is a decade behind.
porsche1945
03/4/2019
16:34
”ViiV Healthcare's Juluca shows sustained treatment effect in studies” Three year results from the SWORD 1 & 2 studies. The results demonstrate that 84% (432/513) of participants who switched from their current three- or four-drug antiretroviral regimen to a 2-drug regimen of Juluca (dolutegravir/rilpivirine) maintained viral suppression (viral load ≤50 copies/mL) and showed tolerability and resistance. hTTps://seekingalpha.com/news/3448006-viiv-healthcares-juluca-shows-sustained-treatment-effect-studies
wbecki
03/4/2019
14:28
Shorts opening over £16? Been selling off over £16 for months.
tim 3
02/4/2019
23:04
Yes going - took me 6 hours on ticketmaster to get them. Should be a good game - not much in the teams
watfordhornet
02/4/2019
18:13
Thats what your Missus told me :-0 Going to wembley sunday? cost me £200 for 3 tickets...lets hope we have to fork out more for the final
dr biotech
02/4/2019
13:36
Oooops! Sold a chunk yesterday at 1600p and as usual looks like a little premature
watfordhornet
01/4/2019
09:29
Short term resistance levels are now 1607 followed by 1625.
steeplejack
29/3/2019
10:16
Or it's a good entry point for a short to hedge a long holding - have I got the bottle?
toffeeman
29/3/2019
10:06
£16 sound barrier ready to blow hold tight,meanwhile Vodafone daily licking continued.
abdullla
29/3/2019
00:00
Market report: Pharmaceuticals were rebounding from the pressure in recent days as the White House renews its efforts to dismantle Obamacare in the courts. Commentary on Bloomberg suggested the move would be very difficult for the Trump administration to pass. HTTPS://www.sharecast.com/news/sector-review/sector-movers-utilities-hit-by-uk-election-worries--3814177.html
philanderer
28/3/2019
16:56
This is a different company than in recent years, top rated personnel in the Parma division and huge growth prospects, whilst the forthcoming splitting off of the Consumer side adds enormous potential so why on Earth sell out now when you can wait and collect the generous dividends in the meantime?
warranty
28/3/2019
15:37
Agree chart wise but hope I'm wrong, this has been very range bound for years.
tim 3
28/3/2019
14:21
Fingers twitching!
abdullla
28/3/2019
11:37
Maybe time to sell a few.
abdullla
28/3/2019
11:11
..if usual pattern is repeated, somewhere between 15.20 and 14.85.....
porsche1945
28/3/2019
09:11
Where to next? ….. Any chartists out there, please? …… ;0)
tradermichael
28/3/2019
07:38
March 27th, 2019 – A study published in the Pediatric Infectious Disease Society concluded saying, ‘if licensed, the Priorix / MMR-RIT vaccine could provide a valid option for the prevention of measles, mumps, and rubella in children, 12-to 15-months-old in the United States. Additionally, these researchers said the ‘Priorix / MMR-RIT vaccine would reduce potential risks of a future vaccine shortage'. This is important news since there have been significant measles and mumps outbreaks in the USA during 2019. In this new study, the researchers assessed the immunogenicity and safety of the Priorix / MMR-RIT vaccine from GlaxoSmithKline (GSK) was compared with those of the existing measles vaccine market leader, MMR II, which is produced by Merck.
tradermichael
Chat Pages: Latest  783  782  781  780  779  778  777  776  775  774  773  772  Older
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190721 23:16:31